Oral targeted therapy shrinks tumors in over 70% of patients with HER2-mutant NSCLC The oral targeted therapy sevabertinib led to tumor reduction and manageable side effects in patients with HER2-mutant non-small cell lung cancer (NSCLC), according to data from a trial led by researchers at The University of Texas MD Anderson Cancer Center.
https://www.news-medical.net/n....ews/20251022/Oral-ta

VT3989 shows promising antitumor activity in refractory mesothelioma patients The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led by researchers from The University of Texas MD Anderson Cancer Center.
https://www.news-medical.net/n....ews/20251022/VT3989-

Researchers highlight ethical implications of clinical trial terminations The termination of thousands of federal grants that fund clinical trials threatens to reverse substantial progress in understanding and treating the health challenges of marginalized populations, particularly children and adolescents who are already underrepresented in research.
https://www.news-medical.net/n....ews/20251022/Researc

Repeated ketamine infusions offer no extra benefit for people hospitalized with depression Findings from a randomized and blinded clinical trial investigating repeated ketamine infusions for treating depression have revealed no extra benefit for ketamine when added onto standard care for people admitted to hospital for depression.
https://www.news-medical.net/n....ews/20251022/Repeate

Novel combination therapy shows promise for advanced neuroendocrine tumors A novel combination therapy pairing a DNA-synthesis inhibitor with a targeted radiopharmaceutical may improve outcomes for patients with advanced neuroendocrine tumors, according to new clinical trial data presented this week at the European Society for Medical Oncology (ESMO) Congress 2025.
https://www.news-medical.net/n....ews/20251021/Novel-c